• Explore /
  • Poster
  • / A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC).

A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC).

Abstract Poster

Authors

null

Andrew Dean

St. John of God Hospital, Subiaco, Australia

Andrew Dean , Li-Tzong Chen , Ramesh K. Ramanathan , Sarah Blanchette , Bruce Belanger , Deyaa Adib , Eliel Bayever

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02551991

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr TPS482)

DOI

10.1200/jco.2016.34.4_suppl.tps482

Abstract #

TPS482

Poster Bd #

O10

Abstract Disclosures

Similar Posters

First Author: Hiral D. Parekh

First Author: Sherise C. Rogers

First Author: Sherise C. Rogers

First Author: Sherise C. Rogers